GS Yuasa Six-Month Ordinary Profit Rises 41% Year-on-Year to JPY 24.37 Billion
Bitget2026/11/06 06:08- GS Yuasa's profit attributable to owners of parent rose 35% year-on-year to JPY 14.17 billion in the six months ended September 30, 2026.
- Net sales climbed 10% year-on-year to JPY 300.23 billion, supported by higher replacement-market lead-acid battery volumes and improved selling prices.
- Operating profit jumped 30% year-on-year to JPY 24.33 billion, helped by Mobility sales volumes, price revisions and a weaker yen.
- Operating cash flow fell 76% year-on-year to JPY 3.49 billion, while cash used in investing activities reached JPY 49.9 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
